SRPT Claude Nicaise sells $248K worth of shares
Mar 14, 2025, 4:33 AM
0.00%
What does SRPT do
Sarepta Therapeutics, based in Cambridge, Massachusetts, focuses on RNA-targeted therapeutics for rare diseases, particularly Duchenne muscular dystrophy, and has developed four approved products. The company employs 1,314 people and has about 40 programs in its pipeline.
Claude Nicaise sold 2,491 shares of SRPT on 12 March at $99.64 per share, worth a total of $248K. They now own 27,812 SRPT shares, or a 8% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.